Taste Masking and Molecular Properties of Metformin Hydrochloride-Indion 234 Complexes

Bhoyar, Pravin K.; Amgaonkar, Yogesh M.

doi:10.4103/0975-1483.80294

Cited by 11 publications

(2 citation statements)

References 10 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The compact mass was collected, grounded, passed through a sieve (ASTM 50), and stored in a desiccator until further use. [11][12][13][14][15][16][17][18][19][20]…”

Section: Extraction Of Dry Water Soluble Mucilagementioning

confidence: 99%

Untitled

2022

IJPBA

View full text Add to dashboard Cite

Introduction: Controlled release drug delivery systems have received much attention in the past two decades with numerous technologically sophisticated products on the market place. Such advancements have come about by convergence of many factors, including the discovery of novel polymers, formulation optimization, better understanding of physiological and pathological constraints, prohibitive cost of developing new drug entities, and the introduction of biotechnology and biopharmaceutical principles in drug product design. The major benefits of these products lie in the optimization of drug input rate into the systemic circulation to achieve an appropriate pharmacodynamic response. Materials and Methods: The drug metformin hydrochloride was selected taking into consideration of their physiochemical, biopharmaceutical properties, and rationale of clinical efficacy. It is an oral hypoglycemic agent; chemically it is 1, 1-dimethyl biguanide derivative, acts by suppressing hepatic gluconeogenesis. It is a white, crystalline powder, and hygroscopic in nature. It is freely soluble in water and slightly soluble in alcohol, practically insoluble in acetone and in dichloromethane. Metformin HCl is readily absorbed from the gastrointestinal tract, having oral bioavailability of 50-60%, peak plasma concentration (Cmax) is reached within 1-3 h with immediate release and 4-8 h with extended release. Plasma protein binding of Metformin HCl is negligible, as reflected by its very high apparent volume of distribution (300-1000 Lit after a single dose). Metformin HCl is not metabolized and excreted as unchanged form in urine, having elimination half-life of 2-6 h. Results: In the present work, the rate of dug release can be prolonged using polymer matrix system, which influences the intragel swelling dynamics and relative physical integrity of the swollen matrix structure. Conclusion: Furthermore, that may produce heterogeneous domains within the swollen gel boundary.

show abstract

“…The compact mass was collected, grounded, passed through a sieve (ASTM 50), and stored in a desiccator until further use. [11][12][13][14][15][16][17][18][19][20]…”

Section: Extraction Of Dry Water Soluble Mucilagementioning

confidence: 99%

Untitled

2022

IJPBA

View full text Add to dashboard Cite

show abstract

“…US Patent 5,024,997 describes taste masking of ibuprofen using hydroxypropyl-beta-cyclodextrin in a palatable solution formulation [57] . Taste masked formulations containing IER complexes of ambroxol [58] , ciprofloxacin [59,60] , levofloxacin [61] , metoclopramide [62] , metformin [63] , ondansetron [64] and risperidone [65] was evaluated. US Patent 5,980,882 describes sustained release drugresin complexes of dextromethorphan coated with ethyl cellulose and stabilized by EDTA as a chelating agent [66] .…”

Section: Taste Masking Technologiesmentioning

confidence: 99%

Solid Oral Flexible Formulations for Pediatric and Geriatric patients: Age-appropriate Formulation Platforms

Ch¹,

rasekaran²,

Ruckmani³

et al. 2018

pharmaceutical-sciences

View full text Add to dashboard Cite

Chandrasekaran and Kandasamy: Solid Oral Flexible Formulation Platform for Paediatrics and Geriatrics The oral route of drug administration is mostly preferred by paediatric and geriatric patients. Patient non-compliance due to poor taste and swallowing problems are major issues in paediatric and geriatric drug therapy. Lack of age-appropriate formulations, inadequate labelling instructions, non-compatible and non-palatable medicines are the main reasons for medication errors in paediatric patients. This review mainly highlights major issues of paediatric and geriatric drug therapy and provides the design of oral flexible formulations as an alternative formulation design for age appropriate formulation development. Development of solid oral flexible formulations as an alternative to existing marketed formulations such as conventional tablets, orally disintegrating tablets, chewable and dispersible tablets for paediatric and geriatrics patients is described. Details about drug properties, excipient selection and taste masking approaches were described. The need for bioavailability and bioequivalence studies for flexible formulations also described. Development of flexible formulations as an alternative to marketed different formulations of the same drug would reduce the cost of the formulation for patients particularly developing countries where accessibility to various types of formulations is less. Flexible tablet formulations can be conveniently used by the patients as orally swallowable, orally disintegrating, chewable and as dispersible tablets. Sprinkle formulations such as pellets, granules packed in capsules or sachets can be conveniently used by paediatric and geriatric patients. Properly designed and developed flexible formulations for new chemical entities and off-patent drugs are need of the hour to provide better treatment to varying age groups of paediatrics and geriatrics.

show abstract